Efficacy of Adjuvant Topical Timolol-Dorzolamide with Intravitreal Bevacizumab Injection in Diabetic Macular Edema: Contralateral Eye Study

Purpose: To evaluate the efficacy of adjuvant topical Timolol-Dorzolamide with intravitreal bevacizumab (IVB) injection on anatomic and functional outcomes in eyes with diabetic macular edema (DME). Methods: In a prospective contralateral eye, interventional pilot study at a tertiary referral academic center, patients with bilateral DME who were treatment naive were enrolled. Enrolled patients received a regimen of topical dorzolamide-timolol twice daily in the right eye and three bilateral monthly IVB injection 1.25mg/ 0.05ml were planned. Baseline central macular thickness (CMT) measured by spectral-domain optical coherence tomography and clinical data, including best corrected visual acuity (BCVA) and intraocular pressure (IOP) , were obtained at enrollment and one month after the third injection. Results: Eleven patients (seven female) with DME were included. BCVA and CMT were improved in both eyes and IOP was decreased in the right eye but was not changed in the left eye. In repeated measures ANOVA analysis, decrease in CMT and improvement in BCVA was significant in the right eye. Conclusion: Data of our study suggest that adjuvant topical Dorzolamide-Timolol in combination with IVB may be further reducing central macular thickness in eyes with DME.